Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Hear me now and understand me later

<< Previous

Bullboard Posts

Next >>

Comment by GameChangerBeton May 20, 2021 11:02am

121 Views

Post# 33237448

RE:Hear me now and understand me later

YukonJezza wrote:
https://youtu.be/7Mk1nykjnYA

If you put in as much time and effort in understanding the business as you do with your continous negative rhetoric, perhaps you might change your stance.

Facts don't care about your feelings.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China